HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 02, 2024 HUTCHMED Limited today announced that, Inmagene Biopharmaceuticals has exercised options to license two drug candidates.
— NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 —— NDA is supported by data from successful Phase III ESLIM-01 trial in patients with adult primary immune thrombocytopenia who have received at least one previous therapy — .
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country s national bureau for drug.